evobupivacaine versus Liposomal Bupivacaine (Exparel®) for Treatment of Pain and Disability in Lateral Epicondylitis – Off-Label, Investigator Initiated Randomized, Controlled, Double-Blind Cross-Over Treatment Trial

Turku University Hospital0 个研究点目标入组 50 人开始时间: 2020年1月7日最近更新: 2020年3月11日

适应症

试验速览

暂无简介。

•-age 18-65
•-chronic lateral epicondylitis (duration >3 months)
•-pain in lateral epicondyle
•-pain in resisted wrist extension in elbow extension (Cozen test)
•-X-ray or Magnetic resonance imaging (MRI) of the elbow (<12 months from enrollment) with no pathological findings other than lateral epicondylitis
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 50
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•-pregnancy
•-unemployment
•-allergy to levobupivacaine, bupivacaine or liposomal bupivacaine
•-constant use of strong analgesics (e.g. opioids)
•-other source of elbow pain (e.g. medial epicondylitis, distal biceps/triceps tendinitis)
•-bilateral epicondylitis
•-inability to give informed consent
•-inability to understand the enrollment forms or to fill patient diary (forms are written in Finnish)
•-previous injection treatment (e.g. cortisone, botulin toxin A, autologous plasma) for lateral epicondylitis during the past 3 months
•-severe hepatic disease, or other underlying severe illness (cardiac failure, cancer, other systemic diseases)

发起方